Table 3.

Univariate and multivariate independent prognostic analysis of 10-gene signature risk score and other clinical characteristics in melanoma patients.

	Univariate analysis		Multivariate analysis
Characteristic	HR (95% CI)	P	HR (95% CI)	P
Training cohort
Age	1.024 (1.004–1.037)	<.001	1.011 (0.997–1.024)	.087
Gender	0.958 (0.665–1.368)	.788	0.892 (0.685–1.423)	.891
T stage	1.575 (1.321–1.978)	<.001	1.532 (1.223–1.916)	<.001
N stage	1.589 (1.352–1.905)	<.001	1.752 (1.383–2.251)	<.001
M stage	1.557 (0.576–4.173)	.387	1.591 (0.521–4.812)	.408
TNM stage	1.568 (1.287–1.912)	<.001	0.767 (0.519–1.129)	.177
Signature risk score	199.59 (20.87–1908.94)	<.001	42.11 (8.243–216.463)	<.001
Validation cohort
Age	1.025 (1.010–1.039)	<.001	1.005 (0.989–1.021)	.547
Sex	1.182 (0.766–1.822)	.451	0.879 (0.556–1.391)	.583
T stage	1.776 (1.437–2.195)	<.001	1.636 (1.267–2.111)	<.001
N stage	1.425 (1.164–1.746)	<.001	1.496 (1.113–2.01)	.008
M stage	3.466 (0.84–14.295)	.086	1.253 (0.283–5.555)	.767
TNM stage	1.607 (1.255–2.058)	<.001	0.978 (0.631–1.516)	.922
Signature risk score	38.93 (6.45–234.94)	<.001	13.54 (1.91–96.19)	.009